following an abbreviated submission:
midazolam (Epistatus®) is accepted for use within NHS Scotland.
Indication under review: treatment of prolonged, acute, convulsive seizures in children and adolescents aged 10 to less than 18 years.
The availability of midazolam (Epistatus) provides a licensed alternative to a previously available unlicensed preparation (10mg/mL).
Download detailed advice135KB (PDF)
- Medicine name:
- midazolam (Epistatus)
- SMC ID:
- Treatment of prolonged, acute, convulsive seizures in children and adolescents aged 10 to less than 18 years.
- Pharmaceutical company
- Special Products Ltd
- BNF chapter
- Central nervous system
- Submission type
- Date advice published:
- 13 November 2017